#news #biotech CureVac’s first-gen COVID-19 vaccine misses the mark with 47% efficacy, as share price halves in after-hours trading

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: CureVac’s first-gen COVID-19 vaccine misses the mark with 47% efficacy, as share price halves in after-hours trading .CureVac’s first-gen COVID-19 vaccine misses the mark with 47% efficacy, as share price halves in after-hours trading
klahucik
Wed, 06/16/2021 – 17:09

from FierceBiotech: Biotech https://ift.tt/3j0j9Cj